Statements (53)
Predicate | Object |
---|---|
gptkbp:instance_of |
gptkb:healthcare_organization
|
gptkbp:bfsLayer |
6
|
gptkbp:bfsParent |
gptkb:Hatfield_and_the_North
|
gptkbp:agent |
single-stranded RNA virus
|
gptkbp:associated_with |
deafness
pancreatitis myocarditis aseptic meningitis increased risk of complications in adults parotitis |
gptkbp:caused_by |
gptkb:mumps_virus
|
gptkbp:complications |
gptkb:psychologist
meningitis orchitis oophoritis |
gptkbp:first_introduced |
gptkb:1967
|
gptkbp:fledging_period |
2 days before to 5 days after swelling
|
gptkbp:global_presence |
declined due to vaccination
|
gptkbp:healthcare |
vaccination campaigns
|
gptkbp:historical_significance |
major cause of childhood illness before vaccine
|
https://www.w3.org/2000/01/rdf-schema#label |
Mumps
|
gptkbp:incubation_period |
16 to 18 days
|
gptkbp:is_monitored_by |
ongoing in many countries
|
gptkbp:is_often_used_in |
gptkb:Person
adults |
gptkbp:is_protected_by |
vaccination
|
gptkbp:is_recognized_by |
1772
|
gptkbp:is_vulnerable_to |
gptkb:MMR_vaccine
second dose at 4-6 years first dose at 12-15 months approximately 88% after two doses |
gptkbp:notable_figures |
Edward Jenner (vaccine pioneer)
|
gptkbp:public_awareness |
important for prevention
|
gptkbp:risk_factor |
college students
young children unvaccinated individuals |
gptkbp:scientific_classification |
recognizes mumps as a vaccine-preventable disease
|
gptkbp:social_responsibility |
gptkb:paramyxovirus
clinical evaluation serological testing boosting vaccination rates documented in various countries seasonal peaks in late winter and spring still occur in unvaccinated populations |
gptkbp:symptoms |
fatigue
headache muscle pain fever 7 to 10 days swollen salivary glands |
gptkbp:transmission |
airborne droplets
|
gptkbp:treatment |
supportive care
relief of symptoms |